Clinical Trial Update: VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial of VNP40101M in combination with Cytarabine for hematologic malignancies (leukemia and myelodysplastic syndromes) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• CYTARABINE (CYTARABINE)
• VNP40101M

Snippet

Sponsor: Vion Pharmaceuticals | Conditions: Leukemia, Myelodysplastic Syndromes | Phase 1 | Status: COMPLETED